Patent 9527864 was granted and assigned to Incyte on December, 2016 by the United States Patent and Trademark Office.
The present disclosure relates to tricyclic heterocycles of Formula I, which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.